OnCo · weekly issue

OnCo weekly, 2026-09-22

416 changelog entries, 1 regulatory event, 2 upcoming dates, 2 corrections. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.

What changed this week

New pages, new data and fixes, from the changelog.

22 September 2026: Registry results for 144 trials, 24 more standard-of-care trials with outcomes, papers and standard-of-care rows linked
22 September 2026: Trial phases read as plain labels everywhere: Platform trial and Observational study instead of Phase platform, with old filter links still working
22 September 2026: A JAMA Oncology 2026 comparison of tissue-free and tumour-informed residual-disease blood tests joins the ctDNA roadmap's sources
22 September 2026: Trial pages say what their enrolment number counts, randomised, analysed or enrolled, with the registry figure explained on hover
22 September 2026: Four new publications found by the registry check are in, including the eight-year ADAURA survival update with its figures, and the check no longer flags screening studies
22 September 2026: Trial enrolment figures now say what they count: 25 landmark trials explain why their randomised or analysed numbers differ from the registry, and five stale figures are corrected from their sources
22 September 2026: MIMic-01 trial status corrected to active against ClinicalTrials.gov, the first fix from the new roadmap registry check
22 September 2026: Every roadmap now carries a registry check: a weekly script compares each referenced trial with ClinicalTrials.gov and Europe PMC, flags contradictions and overdue readouts, and shows the check date under What to watch
22 September 2026: A roadmap and timeline for circulating tumour DNA tests, from the 1948 discovery of cell-free DNA to the residual-disease and multi-cancer detection trials reading out next, with a watch list and a script that checks it against the registries
22 September 2026: Twenty-six landmark papers for the pancreatic cancer pages, from PRODIGE 24 and PREOPANC to the KRAS inhibitor cohorts and the IPMN guidelines, each checked against Europe PMC
22 September 2026: Seventy-four registry trials linked to the newest pancreatic and nasopharyngeal cancer pages, with a guard that keeps neuroendocrine trials off the pancreatic adenocarcinoma pages
22 September 2026: Pages load about three times less script: the header no longer drags in the molecule viewer, every language dictionary and the search engine, so slow connections reach a working page far sooner
22 September 2026: heavy-pages test: explained budget follows the corpus after the trial waves, with the paging rule for the next rise
22 September 2026: Content gaps: the trial-acronym measure treats the programme stem before a hyphen as a known trial name; roadmap notes the 33 remaining tokens are all in the wave SKIP list
22 September 2026: Content wave 3, rare cancers: FIRSTMAPPP, InPACT, GETUG 13, ADIUVO, ADIUVO-2, TROPHIMMUN and BALLAD, 4 with structured outcomes, 4 primary papers, 13 standard-of-care rows linked
22 September 2026: Content wave 3, myeloma: DRAMMATIC (SWOG S1803, MRD-guided maintenance after transplant) recorded from the registry and linked from the myeloma maintenance row; NCI sponsor-of-record institution links removed across the wave
22 September 2026: Content wave 3, endometrial: RAINBO programme (four molecular-class trials including POLEmut-BLUE de-escalation) recorded from the registry; POLE-ultramutated standard-of-care row linked
22 September 2026: Roadmap Progress: wave 7 registry outcomes row (144 of 2,845 ingested trials gain 272 outcome rows from 153 records with posted results; 114 requests)
22 September 2026: Wave 7 data: registry outcomes for the first 2845 registry-ingested trials by family burden (144 trials with 272 outcome rows from 153 records with posted results)
22 September 2026: Content wave 3, ovarian: AURELIA (bevacizumab with single-agent chemotherapy in platinum-resistant ovarian cancer) with structured outcomes and its JCO 2014 paper; two standard-of-care rows linked
22 September 2026: Wave 7 data: registry outcomes for the first 2500 registry-ingested trials by family burden (144 trials with 272 outcome rows from 153 records with posted results)
22 September 2026: Content wave 3, head and neck: CONTINUUM (sintilimab added to induction-concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma) with structured outcomes and its Lancet 2024 paper; standard-of-care row linked
22 September 2026: Wave 7 data: registry outcomes for the first 2000 registry-ingested trials by family burden (111 trials with 209 outcome rows from 117 records with posted results)
22 September 2026: Content wave 3, colorectal: CAPP2 (aspirin in Lynch syndrome, 10-year follow-up) with structured outcomes and its Lancet 2020 paper; Lynch syndrome standard-of-care row linked
22 September 2026: Wave 7 data: registry outcomes for the first 1500 registry-ingested trials by family burden (85 trials with 171 outcome rows from 91 records with posted results)
22 September 2026: Wave 7 data: registry outcomes for the first 1000 registry-ingested trials by family burden (61 trials with 126 outcome rows from 65 records with posted results)
22 September 2026: Content wave 3, lung: IMpower010 is the existing registry record nct02486718, which gains the IMpower010 alias, its positive status and disease-free survival outcomes from the registry results section and the Lancet 2021 report; JCOG0802 skipped (UMIN only)
22 September 2026: Content wave 3, anal family: ANCHOR, POD1UM-303/InterAACT-2, InterAACT and NCI9673 with structured outcomes, 5 primary papers, 6 standard-of-care rows linked
22 September 2026: Explained page: the Open explanation pill carries only its label; glyph and Close state move to CSS; row classes and cross-reference titles shortened
22 September 2026: Content wave 3, sarcoma family: ACTG A5263/AMC 066 (paclitaxel against etoposide or bleomycin-vincristine with antiretroviral therapy for AIDS-associated Kaposi sarcoma) with structured outcomes and its Lancet 2020 paper; Progress table rows for gastric, pancreatic and sarcoma
22 September 2026: Content wave 3, pancreatic family: 7 standard-of-care trials (ESPAC-3, ESPAC-4, CONKO-001, NORPACT-1, LAP07, ESPAC-5, PRECEDE), 6 with structured outcomes, 6 primary papers, 7 standard-of-care rows linked
22 September 2026: LAUNCH: chains 97 and 98 ticked
22 September 2026: Wave 7 data: registry outcomes for the first 500 registry-ingested trials by family burden (39 trials with 78 outcome rows from 40 records with posted results)
22 September 2026: Wave 7 script: fetch-registry-outcomes.ts copies structured outcomes from the ClinicalTrials.gov results section into a side file merged by index.ts
22 September 2026: Content wave 3, gastric family: CLASSIC (adjuvant CAPOX after D2 gastrectomy) with structured outcomes and two primary papers; SKIP list extended for UMIN- and ISRCTN-only trials
22 September 2026: Wave 1 trial papers from Europe PMC, wave 3 standard-of-care trials, wave 5 targets and EMA products and sponsors, seven heavy table pages and idea rankings load rows on demand
22 September 2026: Paged tables: the heavy StaticTable pages carry 30 rows and fetch the rest from /api/v1/tables/
22 September 2026: Content wave 3: structured outcomes for 8 hand-written trials from the ClinicalTrials.gov results section (ARANOTE, CheckMate 915, PACIFIC-2, INTELLANCE-1, ATEMPT, ASPEN, DESTINY-Gastric02, AREN0532); roadmap Progress notes the families not reached
22 September 2026: Content wave 3, lymphoma family: 7 standard-of-care trials (FoRT, GALLIUM, RELEVANCE, TRIANGLE, SYMPATICO, BMT CTN 0803, PTLD-1), all with structured outcomes, 7 primary papers, 9 standard-of-care rows linked
22 September 2026: Content roadmap: wave 5 progress row (targets 30 to 0, EMA products 12 to 0, sponsor companies 21 to 15) with what was not written and why
22 September 2026: Wave 5 sponsor companies: 6 trial sponsors and 2 EMA authorisation holders from Wikidata and the ClinicalTrials.gov sponsor field (Criterium, Artios Pharma, Ambrx, Nerviano Medical Sciences, Qurient, Immunovaccine, Grünenthal, 4SC); drugs and companies waves registered
22 September 2026: Wave 5 EMA products: 7 register products written from their EPAR pages (crisantaspase, burosumab, epoetin theta, human normal immunoglobulin, fentanyl, resminostat, Tacquell), 3 matching faults fixed with aliases, vedolizumab excluded
22 September 2026: Wave 5 targets: 26 pages for the symbols two or more drug records name without a target page (NRAS, CD28, HLA-A, MPL, SHP2, STAT5, IKZF1, JAK1, CD80, ABL1, FAK, IKZF3, PTCH1, CD137, HIF-1α, IDO1, BRD4, IRF4, B7-H4, TET2, NF1, ACVR1, HOXA9, MEIS1, BIM, BAX)
22 September 2026: Content wave 3, childhood family: 9 standard-of-care trials (ANBL1221, ANBL0531, ANBL17P1, AEWS0031, SIOPEL-3, SIOPEL-4, AGCT1531, AHOD1331, EuroNet-PHL-C2), 7 with structured outcomes, 6 primary papers, 11 standard-of-care rows linked
22 September 2026: Content wave 3, brain and CNS family: 10 standard-of-care trials (ACNS1123, ACNS0122, ACNS0333, ACNS0121, NOA-08, SJMB12, ACNS1422, IELSG32, MATRix/IELSG43, INTUITT-NF2), 8 with structured outcomes, 8 primary papers, 12 standard-of-care rows linked
22 September 2026: Content wave 3, leukaemia family: 18 standard-of-care trials with registry records and structured outcomes, 12 primary papers, standard-of-care rows linked
22 September 2026: Fetched paper records link only their trial and journal; wave 1 progress row; citation counts for the new papers
22 September 2026: Idea rankings page carries the first 30 rows of each view and fetches the rest per view from /api/v1/ideas/rankings/<view>.json
22 September 2026: Prostate trials: key papers from Europe PMC for the prostate family
22 September 2026: Skin trials: key papers from Europe PMC for the skin family
22 September 2026: Colorectal trials: key papers from Europe PMC for the colorectal family
22 September 2026: Breast trials: key papers from Europe PMC for 77 trials, 85 new paper records, 22 long-term follow-ups
22 September 2026: Lung trials: key papers from Europe PMC for 125 trials, 134 new paper records, 25 long-term follow-ups
22 September 2026: Cancer map DAG, every hand-written table on the shared header filter, explained page loads explainer bodies on demand, 3,056 corpus-only cross-links
22 September 2026: GuidelineConcordance keeps the guideline body's website link: a small external-link glyph beside each stance chip in the row's cell (sibling anchor, Tab-reachable, tooltip "Open the body's website"), with the test asserting one per body cell and no nested anchors
22 September 2026: Wave 2 corpus-only joins applied: 3,056 links from fields the records already carry, links still to make down from 12,295 to 10,335 Trial to technology 2,743 links on 1,739 trials (modality technologies of the studied agents); technology to trial 211 links, 26 technologies gaining their first trial; idea to trial 133 links on 30 ideas and idea to key paper 46 links on 32 ideas, only where the idea's text names the drug or target in the idea's cancers; drug to key paper 34 links on 25 drugs; drug to trial 35 links where the title names the drug; target drugs arrays 47 links on 21 targets; company to drug 6 links on 5 companies. No EU approval rows written: 59 of the 60 snapshot candidates already had rows and the last is a withdrawn application with no date. No target-to-drug mechanism links: both measured hits were substrings.
22 September 2026: Corpus-only joins script: scripts/link-joins.ts plans and applies wave 2 links from fields the records already carry, with every rule stated; content-gaps measures corrected Ten rules, dry run by default and --apply to write through the editor in scripts/orphan-links.ts (append only, never removes a link, sorted and de-duplicated): trial to technology through the studied agents' modality technologies; idea to trial and idea to key paper only where the idea's own text names the drug or target, in the idea's cancers, for actors that trials test, capped at five and three; company to drug through sponsored trials where the drug has no maker; drug to key paper and drug to trial through titles that name the drug; technology to trial; target drugs arrays mirroring drug.targets; target to drug by whole-word mechanism mention; EU approval rows from the EMA register snapshot with the file's A, C, V and W helpers, product name and snapshot date checked.
22 September 2026: Header filters for the toolbar facets that had no column: CountryRanking gains a Region column, ScorecardTable Type and Country columns (chips that select the value) and a Regions header filter, PipelineFunnel filters the crowding table by approved product and population completeness, ResearchRanking by parent university and five-year coverage; docs/TABLES.md carries every table's state
22 September 2026: Header filters on the client tables that keep their own controls: TrialFinder, TrialFinderGeo, AssistanceBrowser, GuidelineConcordance, ManufacturingMap, InteractionChecker, AutoPulse, SurvivorshipPlan, MarketEstimator, TumorBoard, Navigator and PlanRankings filter from their column headers through useHeaderFilters and FilterHead, sharing state with the existing facet controls where one exists; CaregiverPanel skipped (eight rows, no categorical column)
22 September 2026: Trial key papers fetcher: Europe PMC by registry id, one primary and one follow-up per trial, links merged from trial-key-papers-wave1.ts
22 September 2026: Header filters on every server-rendered table: StaticTable draws plain rows from the page (links, chips, bars, avatars as small objects) so deals, evidence, funding, universities, payloads, costs, status, freshness, eval questions, survival, cited papers, papers pulse, startup investors, audit, review, China trials and deals, India sites, pathway matrix and dossier trials all filter from their column headers with a N of M count and a Clear pill; docs/TABLES.md records every table's state and the skips under ten rows
22 September 2026: Trials in plain words keeps every trial's heading, status, summary and page link in the HTML and fetches the explanation on demand: one file per cancer section, prefetched as the section scrolls near and opened with an Open explanation pill
22 September 2026: LAUNCH: owner asks of 22 Sept 2026 and what shipped in chain 96
22 September 2026: Column headers filter every browser table, tumour testing redesign with laboratory logos, Edge feed, idea and corpus rankings, explore pagination, content roadmap, PR 54 and 55 rows, signed-in bridge
22 September 2026: Cancer map: a layered DAG of every cancer type at /cancers/map/, with organ systems, histology groupings, cancers and subtypes, badges switchable between trials, products, approvals and ideas, an accessible outline, graph.json for agents, and links from the cancer browser and every family strip
22 September 2026: Rankings hub: fourteen league tables computed from corpus counts and dates, one page each with basis, coverage and a JSON companion
22 September 2026: Content roadmap: pages still to write and cross-connections still to make, measured by scripts/content-gaps.ts; waves 143 to 149 on the roadmap
22 September 2026: Edge: one feed of the freshest signals in cancer, new papers, trial results, approvals, withdrawals, law, bot proposals and weekly issues, ranked by recency with a modest importance weight, with Atom and JSON feeds at /edge/feed.xml and /edge/feed.json
22 September 2026: Tumour testing: By scope and By sample become card grids with company logos, and the table filters by sample, scope, laboratory and status from the URL query
22 September 2026: Idea rankings: six views of the same ideas at /ideas/rankings/, every score from existing fields with its formula shown
22 September 2026: Explore, For me and the navigator page their sections: the first 30 rows of each kind ship in the HTML and the rest load per section from static JSON as the reader scrolls or presses Show 30 more; For me and the navigator fetch one file per cancer instead of carrying all 328
22 September 2026: Filter from the column header: every filterable column in the results tables is a button with a funnel glyph that opens a popover of value pills (counts, search past eight, Clear, Close; bottom sheet on phones), wired to the same setter and URL as the toolbar facets; sortable headers keep sort on the label and put the filter on a sibling glyph
22 September 2026: Four EMA application withdrawals recorded as withdrawn rows, melflufen US withdrawal row restored, FDA Tazverik communication dated 11 May 2026
22 September 2026: Bridge to the signed-in site: header greets a signed-in reader, Watch keeps pages on the account with a sign-up offer, a star on every list row, For me can be saved to the account; consent copy
22 September 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
22 September 2026: Upkeep runs on its own: weekly logos, structures, trial links and acronyms, monthly identifiers, and the bots' refreshes now deploy without a manual ship
22 September 2026: Weekly maintenance and monthly identifier workflows; bot pushes now deploy through the Vercel ignore test
22 September 2026: chore: refresh literature snapshot from Europe PMC (#56)
22 September 2026: Add FDA safety communication link and SPM rate to epithelioid sarcoma record
21 September 2026: Trial phases read as plain labels everywhere: Platform trial and Observational study instead of Phase platform, with old filter links still working
21 September 2026: Phase facet test asserts the string key and the shared normaliser
21 September 2026: Facet normaliser is a string key resolved in the client, not a function crossing the server boundary
21 September 2026: Trial phases read "Observational study" and "Platform trial" instead of "Phase observational", from one phaseLabel helper
21 September 2026: A JAMA Oncology 2026 comparison of tissue-free and tumour-informed residual-disease blood tests joins the ctDNA roadmap's sources
21 September 2026: c-TRAK TN tissue-free residual-disease assay paper added and linked from the tumour-informed assay term
21 September 2026: Trial pages say what their enrolment number counts, randomised, analysed or enrolled, with the registry figure explained on hover
21 September 2026: Four new publications found by the registry check are in, including the eight-year ADAURA survival update with its figures, and the check no longer flags screening studies
21 September 2026: Registry check: a non-drug interventional study matches the corpus's observational phase, clearing the PATHFINDER 2 flag
21 September 2026: Four publications flagged by the roadmap registry check recorded as key papers: the ADAURA eight-year overall survival update (J Thorac Oncol 2026) linked from the trial and the EGFR-mutant and resectable NSCLC pages with its stage II-IIIA and IB-IIIA survival figures added to the trial's outcomes, and the FLAURA2 long-term safety analysis (Lung Cancer 2026), the KRYSTAL-12 plain language summary (Future Oncol 2026) and the TROPION-Breast01 China cohort (ESMO Open 2026) linked from their trials only; citation counts fetched from Europe PMC
21 September 2026: Trial enrolment figures now say what they count: 25 landmark trials explain why their randomised or analysed numbers differ from the registry, and five stale figures are corrected from their sources
21 September 2026: Enrolment gaps on 30 roadmap trials reviewed one by one against ClinicalTrials.gov and the primary papers: 25 keep the paper's randomised, analysed, treated or registered count and now say so in a new enrolledBasis and enrolledNote, 5 stale or unsourced figures corrected from the registry or the paper; the roadmap watch reports explained gaps separately and its offline mode re-compares against the committed registry records
21 September 2026: MIMic-01 trial status corrected to active against ClinicalTrials.gov, the first fix from the new roadmap registry check
21 September 2026: Every roadmap now carries a registry check: a weekly script compares each referenced trial with ClinicalTrials.gov and Europe PMC, flags contradictions and overdue readouts, and shows the check date under What to watch
21 September 2026: MIMic-01 status and PATHFINDER 2 design corrected against ClinicalTrials.gov, as flagged by the roadmap watch
21 September 2026: Roadmap watch for every roadmap: scripts/roadmap-watch.ts compares each roadmap's referenced trials with ClinicalTrials.gov (status, phase, enrolment within 5 percent, moved completion dates), lists Europe PMC papers since asOf, flags watch items past their expected date, writes public/roadmap-watch.json for a weekly Thursday workflow and a "Registry check" line on roadmap pages
21 September 2026: A roadmap and timeline for circulating tumour DNA tests, from the 1948 discovery of cell-free DNA to the residual-disease and multi-cancer detection trials reading out next, with a watch list and a script that checks it against the registries
21 September 2026: PATHFINDER 2 status and ECLIPSE enrolment corrected against ClinicalTrials.gov, as flagged by the ctDNA watch script
21 September 2026: ctDNA tests roadmap: ten eras from the 1948 sighting of DNA in plasma to the 2029 randomised readouts, a "What to watch" list with registry and meeting dates, six trials the corpus lacked (TRACC, MERMAID-1 and -2, BESPOKE, CIRCULATE-US, NCI Vanguard), a tumour-informed versus tumour-naive term, and npm run ctdna:watch to keep it current
21 September 2026: Twenty-six landmark papers for the pancreatic cancer pages, from PRODIGE 24 and PREOPANC to the KRAS inhibitor cohorts and the IPMN guidelines, each checked against Europe PMC
21 September 2026: Every pancreatic subtype page now rests on two to four landmark papers: 26 new records (PRODIGE 24, ESPAC-4, PREOPANC, ESPAC5, Alliance A021501, LAP07, CodeBreaK 100 and KRYSTAL-1 pancreatic cohorts, POLO and its survival analysis, the BRCA/PALB2 platinum trial, KEYNOTE-158, the NRG1 fusion discovery and zenocutuzumab papers, Fukuoka, Kyoto and European cyst guidelines, and the acinar cell carcinoma and pancreatoblastoma reference series), each DOI checked on Europe PMC and doi.org, with Le 2017 reused for the MSI-high page and citation counts fetched
21 September 2026: Seventy-four registry trials linked to the newest pancreatic and nasopharyngeal cancer pages, with a guard that keeps neuroendocrine trials off the pancreatic adenocarcinoma pages
21 September 2026: Registry trials now reach the 50 subtype pages added this week: 74 trials linked to the pancreatic disease-state and driver pages and to recurrent or metastatic nasopharyngeal carcinoma, with a neuroendocrine guard so GEP-NET trials stay off the ductal adenocarcinoma pages
21 September 2026: Pages load about three times less script: the header no longer drags in the molecule viewer, every language dictionary and the search engine, so slow connections reach a working page far sooner
21 September 2026: Bundle split follow-ups: stars JSON out of the guarded data folder, layout test reads dictionaries from the full set, row 140 done
21 September 2026: Seven European approvals corrected to withdrawn against the EMA register, the PARTIQoL proton trial gains its reported result, and the KEYNOTE-A18 papers are split into their two Lancet reports
21 September 2026: Client JavaScript on every page cut from 3.0 MB to 1.0 MB: the layout no longer pulls the animated schematics, the structure index, all eight chrome dictionaries, zod or MiniSearch
21 September 2026: Paganetti 2014 RBE reference points at the real paper (Physics in Medicine and Biology)
21 September 2026: Visit counting now asks first: Google Analytics loads only after you allow it, the browser's privacy signal is honoured, and the choice can be changed in the footer
21 September 2026: Data follow-ups: seven withdrawn EU authorisations, PARTIQoL readout, KEYNOTE-A18 split into its two Lancet papers
21 September 2026: Roadmap row 141 marked done for onco.cc
21 September 2026: Google Analytics now loads only after the visitor presses Allow: a consent bar at the foot of the viewport, the choice kept in the browser, Global Privacy Control read as No thanks, an Analytics choice control in the footer and on /privacy/, strings in nine languages
21 September 2026: GitHub star count is baked in at build time, so the top-bar badge is full from the first paint and never flickers
21 September 2026: Launch doc: two dated account notes marked as removed
21 September 2026: Launch doc: old account instructions cut to one-line history notes pointing at me.onco.cc
21 September 2026: Sign in/up opens in the same tab: links to me.onco.cc are treated as part of the site rather than external
21 September 2026: Sign in/up in the top bar now opens the WorkOS sign-in directly, with no stop on a landing page
21 September 2026: Sign in/up on onco.cc now hands you to me.onco.cc, the signed-in side; onco.cc itself keeps no account data, in the browser or the cloud
21 September 2026: Sign in/up now links to me.onco.cc; onco.cc holds no account data
21 September 2026: Sign in/up now goes straight to the WorkOS sign-in page instead of stopping at the newsletter page
21 September 2026: Greptile review config encoding the corpus rules for community pull requests
21 September 2026: Your role, cancer choice and preferences now save to your OnCo account so they follow you across devices, and the outlook block is held back pending a wording review
21 September 2026: Merge cloud profile sync; outlook block held pending wording review
21 September 2026: Community fixes: alphagenome model corrected, epithelioid sarcoma record completed with verified facts, RMC-9805 pancreatic pairing and ubamatamab mechanism corrected, plain-English outlook for ten cancers behind the survival disclosure, and 15 hidden FDA events restored
21 September 2026: Cloud profiles stage one: Supabase tables under the WorkOS token, sync, delete, privacy text
21 September 2026: PR round 2: alphagenome weights gated, FDA regulatory events surfaced, epithelioid sarcoma withdrawal history
21 September 2026: Issues 43, 45, 46, 47: prognosis outlook on ten cancer pages, ubamatamab as MUC16xCD3 bispecific with corrected citation, g12d-plus-pan-ras phase and links from the registry and company release
21 September 2026: Roadmap rows 141 and 142: GDPR compliance for accounts and HIPAA readiness
21 September 2026: chore: render this week's issue to public/newsletter/ (#52)
21 September 2026: chore: refresh public/votes.json from Discussions reactions (#51)
21 September 2026: chore: weekly fact check, audit, and provenance refresh (#50)
21 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#49)
20 September 2026: Fix duplicate entry for 'alphagenome' in model registry
18 September 2026: Health data compliance analysis: HIPAA does not apply today, GDPR and state health-data laws do; stay browser-only and prepare encrypted sync
18 September 2026: Top bar sign-in works even before the page script loads: it is now a link that upgrades to the direct WorkOS start
18 September 2026: Top bar button shortened to Sign in/up in every language, and cached pages refreshed so everyone sees the new header
18 September 2026: After sign-in a welcome page asks who you are and which cancer, the top bar shows you are signed in, four community pull requests and four issue fixes land, and secret scanning guards every commit
18 September 2026: Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics
18 September 2026: Welcome step as its own page: sign-in leaves /signup/ for /welcome/ or the return path, signed-in header pill, preferences kept with the account profile
18 September 2026: Secret scanning: gitleaks on every push and pull request, a local pre-commit hook, and an allowlist for public ids and data prose
18 September 2026: Sign up or log in button in the top bar, a medical disclaimer in the footer, and new Terms of Use and Privacy Policy pages
18 September 2026: Trastuzumab carries the June 2026 FDA approval of palbociclib with trastuzumab as HER2-positive maintenance, the one bot proposal from PR 35 not already in the corpus
18 September 2026: Pages are far lighter: the shared header, footer and cancer list are no longer copied into every page's data, and the sign-in id ships with the code
18 September 2026: Terms of use and privacy policy pages, medical disclaimer in the footer, copyright to OnCo
18 September 2026: Header: a Sign up or log in pill when signed out; region, language and search controls sit on the centre line
18 September 2026: Stop serialising the cancer list and the shared chrome into every page's payload
18 September 2026: Sign-in is live: first-time visitors choose whether they are a patient, caregiver, researcher or clinician and can set a cancer, kept only in their browser
18 September 2026: Each ship now builds once: Git-triggered Vercel builds are skipped and only the verified deploy runs
18 September 2026: First sign-in welcome step: who you are, optional cancer, browser-only profile per WorkOS user
18 September 2026: Vercel: skip Git-triggered builds so each ship builds once, from the verified CLI deploy
18 September 2026: add: Strand AI (W26) to the YC oncology list
18 September 2026: Owner list: proposal for six technology sections to lift the section kind past the size gauge
18 September 2026: Every reference DOI on the site checked against Europe PMC: four wrong links corrected, and a checker script added for future waves
18 September 2026: DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added
18 September 2026: Sixty-six landmark and classification papers for the rare-cancer pages, each checked against Europe PMC, plus two corrected reference links
18 September 2026: Two rare-cancer reference links corrected to the verified POD1UM-303 Lancet 2025 and MEK inhibition Nature 2019 papers
18 September 2026: Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR and ACT II to FIRM-ACT, PATHFINDER, HD21 and FIRSTMAPPP, linked through keyPapers
18 September 2026: Fifth Chinese quality pass over the new rare and pancreatic cancer pages: 14 corrections
18 September 2026: Four pancreatic Chinese TL;DR fixes synced from the wave export into the dictionary
18 September 2026: Chinese TL;DR pass 5: fix 14 rare and pancreatic subtype entries
18 September 2026: Eleven pancreatic cancer pages by stage and driver, from resectable and borderline disease to KRAS G12C, BRCA-mutant and MSI-high tumours, each linked from its trials and drugs
18 September 2026: Add 11 pancreatic cancer subtype pages: stage, driver and histology
18 September 2026: Thirty-nine subtype pages for rarer cancers, from anal and vulvar cancer by HPV status to Hodgkin lymphoma by stage and mastocytosis, plus an IndexNow script for changed pages
18 September 2026: Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adrenocortical, appendiceal, small bowel, cancer of unknown primary, histiocytoses, Langerhans cell histiocytosis, systemic mastocytosis, Hodgkin lymphoma, gestational trophoblastic neoplasia, pheochromocytoma and paraganglioma, nasopharyngeal and sinonasal cancers, with organ-drawing mappings, reverse links from 76 existing trial and drug records, Chinese TL;DRs registered for fold-zh and parent phrases for the cancer-families test
18 September 2026: IndexNow script: submit record pages changed since a date, batched, with a dry run
18 September 2026: Target pages with a mutation hotspot map no longer throw a hydration error: chart tooltips are written as single strings, and the page test now checks markup structure
18 September 2026: Fix hydration error 418 on target pages: multi-child SVG titles rendered empty by the server
18 September 2026: Fourth Chinese quality pass: 22 corrections across researcher, institute, trial and company summaries, including arsenic trioxide and enzalutamide names
18 September 2026: Chinese quality pass 4 over 243 folded TL;DRs
18 September 2026: Thirty-five key papers gain their DOI and PubMed ids, so every key paper but one now shows its citation count
18 September 2026: Add DOIs and PMIDs to 35 key papers that had neither
18 September 2026: Drug cards no longer nest a link inside a link, and a permanent test renders every page to forbid nested anchors site-wide
18 September 2026: Gene targets carry HGNC, Ensembl, UniProt and NCBI Gene identifiers, and key papers show how often they have been cited
18 September 2026: Guard every page against nested anchors; unnest the product card
18 September 2026: Roadmap rows 22 and 97 marked done
18 September 2026: TRACERx 2023 paper DOI corrected (ends -5, verified at doi.org)
18 September 2026: Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets
18 September 2026: Citation counts for key papers from Europe PMC (improvement 97)
18 September 2026: Dependency map hydration error fixed: vendor tiles no longer nest a link inside a link, with a test that forbids nested anchors
18 September 2026: Fix React 418 on the dependency map: no anchor inside an anchor
18 September 2026: Health pass: 369 paper links for 270 researchers, PubChem structures for 43 drugs, six glossary Wikipedia links, refreshed literature snapshots for all 2,093 tracked records, provenance for every record, and 28 logos
18 September 2026: Six more glossary terms gain Wikipedia links; 74 recorded as having no article
18 September 2026: Molecules for 43 more small-molecule and peptide drugs via PubChem name lookup
18 September 2026: Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%
18 September 2026: Trial acronym aliases completed for every registry trial that has one (115 more), so searches by study name find them all
18 September 2026: Add 115 registry trial acronyms from the CT.gov acronym field
18 September 2026: Eighty more drug companies gain Wikipedia and Wikidata links
18 September 2026: Add Wikidata ids and Wikipedia links for 80 more companies
18 September 2026: Sixty-three more institutes and 48 drug companies gain Wikipedia and Wikidata links for readers and machines alike
18 September 2026: Add Wikidata ids and Wikipedia links for 48 companies
18 September 2026: Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API
18 September 2026: Sixty-six hospitals and institutes gain Wikipedia and Wikidata links, which also feed the machine-readable sameAs data for agents
18 September 2026: Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API
18 September 2026: Final researcher identifiers pass: 64 ORCID ids and 60 Wikipedia links, taking 373 people to ORCID and 181 to Wikipedia, plus STRASS trial results
18 September 2026: Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass
18 September 2026: Seventy-seven landmark trials now show their results as structured outcomes transcribed from the published abstracts, and 146 more researchers carry ORCID ids
18 September 2026: Add structured outcomes to STRASS from its Lancet Oncology 2020 abstract
18 September 2026: Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people
18 September 2026: Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts
18 September 2026: A further 121 researchers carry ORCID ids and 18 gain Wikipedia links, each checked against their ORCID employment record
18 September 2026: Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass
18 September 2026: Subtype cancer pages now link their sibling subtypes (667 links) and 188 researchers carry ORCID ids with 22 Wikipedia links
18 September 2026: Add 188 ORCIDs and 22 Wikipedia links to people records
18 September 2026: Forty-one hospitals and institutes added and 78 researchers linked to where they work
18 September 2026: Link cancer subtypes to their siblings and name parents in tldrs
18 September 2026: Fill institutions for 78 trial investigators and add 41 institution records
18 September 2026: Five duplicate person pages merged into one each with redirects, and a duplicate finder for people added
18 September 2026: Merge five duplicate person records and add a duplicate-person finder
18 September 2026: Update weights and URLs for alphagenome model
18 September 2026: A hundred and eleven trial leads and first authors get person pages, linked from the landmark trials and key papers they led, plus 160 more trial acronyms
18 September 2026: A further 160 trial acronyms added as aliases to registry trial records
18 September 2026: Add 111 trial investigators and lead authors named by the subtype trials and key papers
18 September 2026: Trial acronyms (MARIPOSA-2, SPARTAN, CheckMate 9DX and 700 more) added as aliases to registry trial records so searches by the name patients hear find them
18 September 2026: Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases
18 September 2026: Seventeen more landmark trials named on subtype pages (ATTRACTION-2, MAIA, RESONATE-2, NeoSphere and others) recorded with confirmed registry ids, and acronyms added to three registry records
18 September 2026: Third Chinese quality pass: 19 corrections to new drug, company and trial summaries, including wrong drug names and Korean text left in Chinese sentences
18 September 2026: Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled
18 September 2026: Third Chinese quality pass: 19 of 236 TL;DRs from the biomarker, drug, maker and trial waves corrected, and the 73 trial TL;DRs folded into zh.ts
18 September 2026: Seventy-three trials named on subtype pages now have their own records with confirmed registry ids, plus logos for the new drug makers
18 September 2026: Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)
17 September 2026: Seventy-four drug makers added and 210 drug-to-company links filled, so pipeline drugs now show who is developing them
17 September 2026: Link 193 company-less drugs to their makers and add 74 maker records
17 September 2026: Key papers for 147 subtype pages: 364 pivotal trial, classification and guideline papers, each checked against Europe PMC
17 September 2026: Add key papers to 147 cancer subtype pages
17 September 2026: Thirty-nine drugs named by the new subtype pages now have their own records, from hormone therapies for pituitary tumours to antibody-drug conjugates in trials
17 September 2026: Add drugs named by the cancer subtype pages (drugs-subtypes-wave)
17 September 2026: Fifty biomarker glossary terms named by the new subtype pages (molecular groups, risk scores, resistance mutations), each linked from the pages that use it
17 September 2026: Add 50 biomarker terms named by the cancer subtype pages
17 September 2026: Registry trials linked to 109 subtype pages by driver and stage (1,018 links), with a re-runnable matcher script
17 September 2026: Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens
17 September 2026: Plain-English sentences for the 170 new subtype pages and trials, so every record carries one again
17 September 2026: Add simple sentences for the subtype-wave cancer pages and trials (part-s)
17 September 2026: Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;DRs from tonight's new pages, including one inverted meaning, and adopts NMPA drug names
17 September 2026: Review Chinese TL;DRs of the subtype waves: standard drug names, terms and alignment with the English
17 September 2026: Merge duplicate trial records onto their named keepers
17 September 2026: Head and neck cancers by HPV status and site: HPV-positive and HPV-negative disease, recurrent or metastatic squamous cell carcinoma, hypopharyngeal cancer, three salivary gland histologies and three oral cavity subsites, tied to KEYNOTE-048, RTOG 1016, De-ESCALaTE, ECOG 3311, PATHOS and NIVOPOSTOP
17 September 2026: Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic state page, hypopharyngeal, adenoid cystic, salivary duct, mucoepidermoid, oral tongue, gingivobuccal (India) and lip, with NIVOPOSTOP, ECOG-ACRIN E3311, PATHOS and CAPTAIN-1st
17 September 2026: Neuroendocrine neoplasms by site and grade: small intestinal, pancreatic and lung neuroendocrine tumours, grade 3 NET and extrapulmonary neuroendocrine carcinoma, tied to NETTER-1 and 2, CLARINET, PROMID, RADIANT and CABINET; NETTER-2 refiled under neuroendocrine cancer
17 September 2026: Add neuroendocrine subtypes by site and grade
17 September 2026: Childhood cancers by type and risk: acute lymphoblastic leukaemia by risk group, Philadelphia status, infancy and relapse, paediatric AML, neuroblastoma by risk group, medulloblastoma by molecular group, and a page for adolescents and young adults
17 September 2026: Add paediatric cancers by type and risk group
17 September 2026: Sarcomas and bone tumours by type: chondrosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, alveolar soft part sarcoma, PEComa, epithelioid haemangioendothelioma, nerve sheath tumours, retroperitoneal and extremity soft tissue sarcoma, with STRASS, EORTC 62012, AMPECT and ANGIOTAX
17 September 2026: Add sarcoma and bone tumour subtype pages with landmark trials
17 September 2026: Cancer pages by state for the common cancers: gynaecological cancers by molecular class and stage, skin cancers by state, lung cancer by driver and stage, breast cancer by state, 44 pages tied to their landmark trials and drugs; the My cancer chip leaves the header until accounts are on
17 September 2026: Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive brain metastases, early and metastatic triple-negative, inflammatory breast cancer, Paget disease of the nipple and phyllodes tumour, each linked from the trials and drugs that treat them
17 September 2026: Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials
17 September 2026: Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP
17 September 2026: Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or recurrent endometrial cancer, uterine carcinosarcoma, cervical cancer by stage (early and fertility-sparing, locally advanced, recurrent or metastatic) and ovarian cancer by platinum sensitivity, each tied to its landmark trials and drugs
17 September 2026: Blood cancers by state: acute myeloid leukaemia by driver and fitness, acute promyelocytic leukaemia, myeloma from smouldering to relapsed, MDS by risk, CLL by line and Richter transformation, CML by phase and primary myelofibrosis, nineteen pages tied to 111 drugs and trials
17 September 2026: Blood cancers by driver, state and phase: nineteen subtype pages
17 September 2026: Upper gastrointestinal and liver cancers by state: gastric cancer by HER2, CLDN18.2, PD-L1 and MSI status and early gastric cancer, hepatocellular carcinoma by BCLC stage, intrahepatic and extrahepatic cholangiocarcinoma, and GIST by mutation, each tied to its landmark trials and drugs
17 September 2026: Colorectal cancer by state: rectal, MSI-high, BRAF V600E, HER2-amplified, KRAS G12C and early-onset pages with OPRA, PROSPECT, BEACON and other landmark trials; primary mediastinal B-cell lymphoma
17 September 2026: Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIST by mutation
17 September 2026: Brain tumour subtypes: IDH-mutant astrocytoma, oligodendroglioma, meningioma, brain metastases, paediatric high-grade glioma, spinal cord tumours, vestibular schwannoma and CNS germ cell tumours, each linked from the drugs and trials that treat them
17 September 2026: Add colorectal subtype pages and primary mediastinal B-cell lymphoma
17 September 2026: Add brain and spinal tumour subtype pages
17 September 2026: Plain-English sentences for every remaining record: 1,167 early-phase trials, 138 people, 65 companies, 8 institutions and 3 ideas, so all 11,306 records now carry one
17 September 2026: Simple layer: part-r, fourth and final wave to full coverage
17 September 2026: Websites for 15 organisations and nine more logos, with archived addresses replaced by live sites; roadmap row 139 records the open dependency map hydration mismatch
17 September 2026: Add official websites to 15 sponsor records and fetch nine logos
17 September 2026: Roadmap row 139: dependency map hydration mismatch
17 September 2026: 969 more plain-English sentences for early-phase trials, key papers and collections, taking the simple layer to 9,930 records; one non-cancer registry record removed
17 September 2026: Simple layer wave 3: part-q with 969 sentences (trials, papers, collections)
17 September 2026: Orphan trials given content: ten drug matches, 17 sponsor aliases, 36 sponsor companies and 130 trials tied to their makers, two non-cancer records removed; backlinks round: 303 weakly linked records gain true relations from their own text; orphans down to 214
17 September 2026: After the trial removals: no dangling references, floor re-run, sponsor wave three Chinese folded
17 September 2026: Backlink fill: text-supported relations for 303 weakly connected records
17 September 2026: 1,024 more plain-English sentences: 279 companies, 104 institutions and 640 phase 3 trials, taking the simple layer to 8,961 records
17 September 2026: Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (wave 3); remove two myasthenia gravis records
17 September 2026: Papers for 36 more researchers matched by institution; trial snapshots refreshed for all 1,024 products with 136 registry changes detected; paper snapshots refreshed for all 1,924 records
17 September 2026: Add simple part-p: 1024 plain sentences for companies, institutions, the theories pathway and phase 3 trials
17 September 2026: One papers block per person after the two paper waves met
17 September 2026: People papers: 36 more research-trained people via OpenAlex and Europe PMC
17 September 2026: docs(corrections): name the reporting clinician on the two glioblastoma rows
17 September 2026: Company content and sources for 33 makers, 26 sponsor corrections and papers for twelve researchers; 7,065 reverse links take orphaned trials from 2,467 to 279; Wikipedia links for six terms; structured outcomes with sources for 26 trials; 153 new logos; the schematic gauge counts aliased drawings
17 September 2026: Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge
17 September 2026: Schematic gauge counts aliased drawings as specific
17 September 2026: Add Wikipedia links to six terms lacking one
17 September 2026: Fold a doubled relation line after the sponsor merge
17 September 2026: Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them back; orphan floor 2572 to 384
17 September 2026: Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people
17 September 2026: 661 plain-English sentences: every cancer, 201 drugs, 179 technologies, 120 terms, 50 phase 3 trials and 63 targets; 451 reverse links give 126 orphaned drugs and 105 companies their first inbound link, with three maker corrections
17 September 2026: Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list them back; orphan floor 2827 to 2572
17 September 2026: Simple layer: part-o with 661 sentences, layer test
17 September 2026: Machine translation pipeline for record summaries with hash-checked cache and a report link; 157 Chinese summaries live (every cancer page and nine glossary terms) and two Spanish; model review panel populated for twenty cancers by Fable, each verdict tied to the record's own sources
17 September 2026: Every record has its own RDF Turtle file at /api/v1/rdf/<id>.ttl, linked from the page head, the hidden machine links, JSON-LD, the OpenAPI document and llms.txt
17 September 2026: Machine-translated summaries: cached per record and language under public/i18n/summaries, shown only while the English hash matches, marked as machine translated with a report link and an English toggle; prioritised batch script with a fetch call to the Messages API and a validator for NCT ids, doses, gene symbols and leftover English; hand-written Spanish and Chinese examples for pCR; coverage script counts them
17 September 2026: Per-record RDF: one Turtle file per record at /api/v1/rdf/<id>.ttl, linked from every record page
17 September 2026: For me from a real situation: setting, biomarkers, treatments had, country and trial interest drive what is standard, what your biomarkers change, trials that fit, warnings and questions, all from record fields with sources; dependency map renders identically on server and client
17 September 2026: Theme stays light even when React recovers from a hydration mismatch; the counts grid fills its rows again with twenty kinds
17 September 2026: Fix hydration mismatch on the dependency map
17 September 2026: For me from a real situation (roadmap item 101): setting, biomarkers, treatments had, country and trials drive record-backed sections
17 September 2026: Machines of oncology, second wave: 23 more machine families from boron neutron capture and FLASH beams to hyperthermia, fluorescence surgery, positioning, gating and dosimetry, with 32 vendors; roadmap rows marked done for the day's work
17 September 2026: Decisions you may face: a page per cancer laying out each treatment setting's options, evidence and trade-offs; expert centres as a sortable table of what can be measured, with a near-you marker; your remembered cancer follows you through the header, home, hubs, trials and search; a what-changed page per cancer; red cards for warnings on cancer pages
17 September 2026: Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, endoscopy, skin and cervical imaging, RT guidance and QA, CSTDs
17 September 2026: Prostate cancer by state: eight subtype pages from low risk to neuroendocrine, linked from 45 trials and drugs; Tregzi added from the FDA notice and the remaining update bot proposals checked against the registry; Hansoh merged into one record with a redirect
17 September 2026: Patient roadmap 102, 104, 106: remembered cancer, per-cancer what changed, red cards
17 September 2026: Decision pages per cancer and outcome-based centre tables (roadmap items 107 and 108)
17 September 2026: Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge
17 September 2026: Chinese quality pass: 82 TL;DRs corrected (standard NMPA drug names, basket trial term, methotrexate spelling, idioms), account strings in the formal register
17 September 2026: Radiation wave 5: LET, RBE and when protons beat IMRT
17 September 2026: Chinese quality pass on today's TL;DRs and interface strings: 篮式试验 for basket trial, 甲氨蝶呤 typo, 磁共振直线加速器, established drug names in 61 templated trial lines, natural wording in 30 machine-flavoured sentences, 您 throughout the account strings
17 September 2026: First sixty days after diagnosis: a week-by-week guide for every cancer built from its records, and a printable appointment sheet per cancer with questions, words you may hear and treatments you may be offered
17 September 2026: Model review panel: schema, batch script and page for AI model commentary on records, with two example panels; diagnostics wave two: 24 tests from RAD51 foci and CTC counts to pharmacogenomics, cardiac markers and low-resource screening, with five companies; institution networks: Parker Institute members and leaders, CRUK, NCI, UNICANCER and DKTK links, and ten weakly linked centres strengthened
17 September 2026: Add the first 60 days guide and per-cancer appointment sheets
17 September 2026: Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institution pages
17 September 2026: Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)
17 September 2026: Animations pause off screen, when the tab is hidden and on slow phones, with a shared budget of six spinning molecules or drawings at once; the record page sidebar stays inside its column and never reaches the footer
17 September 2026: Model panel: AI models comment on records beside the human review path
17 September 2026: Search results page as an index: kind chips, did-you-mean, pages strip, Ask OnCo card, related strip; 29 trial design terms and a design picker page; startup requests ranked by urgency and commerciality with every input cited; 51 law and regulation terms by jurisdiction with a law page; translation hygiene: language tags, no-translate on names and doses, a browser translation offer
17 September 2026: Animation budget for slower phones: one hook (use-animation-budget) pauses molecules, wireframe schematics, the docking scene, the garden sway, the body map, the resistance map and the steppers when off screen or the tab is hidden, draws a still frame under reduced motion, caps thumbnails at six spinning per kind, animates on tap on Save-Data or four-core devices, defers structure fetches until on screen, lazy-loads the gallery 3D viewer; record page sidebar confined to its grid column and not sticky when taller than the viewport; roadmap rows 127 and 138
17 September 2026: Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)
17 September 2026: Manufacturing in oncology: seven supply chains, 18 technologies and 14 makers; theories of cancer: a hub map and sixteen theory records with status; platform trials at depth: 21 master protocol trials and a hub term; technology dependency map with 119 edges and a viewer; Chinese TL;DRs folded in for every new record
17 September 2026: Browser translation and language attributes (roadmap row 128, part three): summaries, field values, data tables, bullets and table bodies carry lang="en" while TL;DRs keep their own language; drug, gene, company, trial and person names, aka lines, NCT ids, gene symbols, database ids, molecule labels, formulas and doses carry translate="no" with the notranslate class; TranslateOffer shows one dismissible line at the top of the main column that switches to a carried language or explains the browser's translator in nine languages; wireframe canvas labels repeated as hidden real text; scripts/translation-coverage.ts measures the share of a page in the chosen language per kind
17 September 2026: Rank startup requests by urgency and commerciality (row 112)
17 September 2026: Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)
17 September 2026: Search results page as a proper index (roadmap row 123)
17 September 2026: Manufacturing wave: remove the Hitachi remnant
17 September 2026: Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella trials, STAMPEDE enriched
17 September 2026: Theories of cancer: hub map and sixteen theory records in the mechanics section
17 September 2026: One Hitachi record (machines wave)
17 September 2026: Machines of oncology: 21 machine technologies, 17 vendors and 66 centres with their proton, carbon, MR-linac, Gamma Knife and other rare machines, with a machines page; Free in oncology page with 62 services; tumour sequencing tests compared across 13 laboratories; useful 404 page with nearest matches; section tabs, aligned header icons and unsqueezed tables; machine-readable links, Wikidata sameAs and short titles for search engines and agents; footer credit; navigation starts at the top
17 September 2026: Technology dependency DAG viewer (roadmap 134)
17 September 2026: Manufacturing wave: seven supply chains, 18 technologies, 14 makers
17 September 2026: Merge fixes: single Strata Oncology record, Chinese dictionary without duplicate keys
17 September 2026: Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres
17 September 2026: Free in oncology and tumour sequencing test pages (roadmap 117, 118)
17 September 2026: SEO and agent surface on record pages: titles within 60 chars, Wikidata sameAs, hidden machine-readable landmark
17 September 2026: Compact section tabs, table column widths and header icon alignment
17 September 2026: Make the 404 page useful: nearest matches, ways in, local miss log
17 September 2026: Tables: one shared stand-in for rows with no picture, so no visual slot is ever an empty gap
17 September 2026: Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall through to the profile link; drawer close button without a border; pills never break inside a word; page titles capitalised; landing cards show a corner arrow; off-site links open in a new tab; intoDNA STRIDE and Strata Oncology with sequencing links for testing companies; roadmap rows 115 to 121
17 September 2026: Accounts through WorkOS: browser-only sign-in behind the same account functions, recorded in WorkOS, on when the client id is set; README retitled Total information dominance on cancer with an open-repository note and a screenshot gallery; site title to match; pivot modality headers use one classifier so every header links
17 September 2026: Search index is fresh on every visit (service worker network-first for the API, cache rule narrowed to snapshots and images); site pages ranked higher in search; models table shows each maker's logo or an initials tile; orphan detector script and ratchet test; hub page linked from digital twins
17 September 2026: Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancreatic cancer wave: four failed phase 3 programmes, nimotuzumab's NOTABLE approval, elraglusib, their sponsors and cross-links; PDAC and Cloudflare rows on the roadmap
17 September 2026: Merge PRs 25, 28 and 29 (CheckMate split, topic cards, WebMCP); mobile region menu stays on screen; one heading per cancer group; bevacizumab NICE note; glioblastoma MGMT and tovorafenib wording; mathematical models hub and site pages in search; long lists load in pages as you scroll
17 September 2026: Add progressive WebMCP tools for public oncology search and lookup
17 September 2026: fix: filter cancer topic cards by relevance
17 September 2026: fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6
17 September 2026: Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-long cache headers for snapshots; Cloudflare caching on the roadmap
17 September 2026: Changelog sync keeps the pending entry through the build
17 September 2026: Changelog kept current from the commit log; linked from the README
17 September 2026: Link 51 new technologies back from their drugs, targets and base drawings
17 September 2026: Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers
17 September 2026: Link 28 cancer subtype pages from the drugs and trials that treat them
17 September 2026: Refresh provenance for this week's records
17 September 2026: Cancer links for 20 unlinked trials; Chinese version complete for trials
17 September 2026: Watch button confirms each click
17 September 2026: Country pages: cancer site labels link to their OnCo pages in both tables
17 September 2026: Chinese TL;DRs for the last 87 curated trials and drugs
17 September 2026: Mathematical and biophysical models: 22 model technologies, a third type on the models page
17 September 2026: Types strip as pills, navigator visuals, account-style signup, linked grid headers
17 September 2026: chore: refresh pulse, abstract and citation snapshots (#20)
17 September 2026: chore: refresh institution research output from OpenAlex (#17)
17 September 2026: chore: draft change proposals from feed snapshots
16 September 2026: Add Anocca; biophysics sources as data-source candidates
16 September 2026: Prevalence rows for 20 more targets
16 September 2026: Prevalence rows for 36 targets
16 September 2026: Molecules for 26 more drugs and tracers
16 September 2026: Molecules for 29 more small-molecule drugs
16 September 2026: Pipelines and missing rows for 29 new cancer pages
16 September 2026: Keep the corpus out of the tool pages' JavaScript
16 September 2026: Keep the corpus out of the guideline pages' JavaScript
16 September 2026: Load translation tables on demand; Chinese TL;DRs for 2,678 registry records
16 September 2026: Chinese TL;DRs for the remaining 131 people
16 September 2026: Subtype pages: leiomyosarcoma, liposarcoma, synovial sarcoma, marginal zone lymphoma, cutaneous T-cell lymphoma
16 September 2026: Subtype pages: kidney, testicular, oesophageal, bladder
16 September 2026: Fix accessibility regressions in shared UI components
16 September 2026: Subtype pages: thyroid, head and neck, ovarian
16 September 2026: Chinese TL;DRs for every company, institution, term and idea
16 September 2026: Radiation wave 4 (21 landmark trials) and Chinese TL;DRs for every cancer, target, technology and curated drug
16 September 2026: Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs
16 September 2026: check-links: separate blocked from broken in the report (#15)
16 September 2026: Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112
16 September 2026: Mobile search opens into the box; radiation wave 1
16 September 2026: Add SciRouter, a prevention-first longevity start-up
16 September 2026: Molecules for 31 small-molecule drugs; gumarontinib folded into glumetinib
16 September 2026: Essential thrombocythaemia page, aspirin record, vorolanib
16 September 2026: Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas
16 September 2026: China deep dive: fifteen trial sponsors as company records
16 September 2026: Offline page only on real failures, China wave 1, favicon set
16 September 2026: Registry trials wave 6 and products wave 7
16 September 2026: Clickable breadcrumbs, pipeline products wave 6, checklist additions
16 September 2026: Header signup, trial wave 5 and Ask weighting
16 September 2026: trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recorded drug and cancer (295 to their sponsor); wave 3 trials gain sponsor links; search lifts the kind named at the start of a question so a 'drug for' query ranks drugs above trials and people
16 September 2026: data: pipeline wave 2 from ClinicalTrials.gov, curated: 27 products missing from the corpus (ten China-approved kinase and checkpoint drugs, Japan's amrubicin and pirarubicin, tabelecleucel, HER2 and GDF-15 antibodies, PSMA and CAIX PET tracers, CD45 radioimmunotherapy and others) with 32 phase 3 trial records and China regional rows; launch checklist gains the agentic and AI accessibility to-do
16 September 2026: cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer, NUT carcinoma) with state of the art, history and development pipelines; six trials (TIGER, SABR-COMET, the tazemetostat run-in, three NUT carcinoma trials) and the BET inhibitor ZEN-3694; gaps page counts only developers as missing products
16 September 2026: site: Google Analytics tag with an honest disclosure on the about page; refresh workflows merge their own pull requests once validate and tests pass (the proposals workflow stays a human gate); deploys the FCCT directory and the nine merged weekly snapshots
16 September 2026: chore: draft change proposals from feed snapshots (#1)
16 September 2026: chore: refresh pulse, abstract and citation snapshots (#2)
16 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#3)
16 September 2026: chore: refresh public/votes.json from Discussions reactions (#5)
16 September 2026: chore: weekly citation link check (#7)
16 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#8)
16 September 2026: chore: refresh preprint tracker from Europe PMC (#9)
16 September 2026: chore: check regional approvals against the EMA register (#10)
16 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#11)
16 September 2026: data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and the FCCT directory brought in: 39 suppliers, tools and services and 10 clinics and centres for tissue preservation, tumour profiling, functional drug testing, liquid biopsy, theranostics, vaccines, cell therapy, trial finding and navigation
16 September 2026: owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton therapy trial and an idea on why ADCs have failed in mesothelioma; cancer pages replace the curated Pipeline list with an In development tab built from the whole corpus; Even One Ventures and fourteen portfolio companies with a weekly-refreshed universe list
16 September 2026: data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indication (historic hormonal and cytotoxic agents, photodynamic and diagnostic agents, growth factors, antiemetics, drugs approved in Japan, China, India or Australia); approval pill no longer wraps
16 September 2026: header: profile icon on every page opens an email capture dialog (magic-link sign-in when accounts are on, list endpoint otherwise); weekly-issue signup boxes removed from footer and newsletter page; strings in nine languages

What changed in release 1.0.0 (2026-09-16)

New pages, new data and fixes, from the changelog.

Added: Glossary: twenty canonical categories (mapped at load from the labels written across the data files), one regular category grid with an animation for every category, and a specific picture on every term that has one (its target's schematic, its molecule, its technology's schematic or the organ it concerns) in the table and at the top of the term page.
Added: Email signup: a SignupBox in the footer and on /newsletter/, driven by NEXT_PUBLIC_SIGNUP_ACTION (Buttondown or Listmonk form endpoint); until it is set the box offers the Atom feed and the per-page Watch button.
Added: Initials placeholder (RowAvatar) for startups, organisations and people without a usable logo or portrait; hotlinked favicons that fail or come back as the generic 16 px globe fall back to it.
Added: Journal wordmarks for Nature, the New England Journal of Medicine, Science and The Lancet from Wikidata via their Wikipedia titles, shown on the journals index and journal pages.
Added: Seventeen ChEMBL drug targets (SRC-family kinases, GM-CSF and IL-11 receptors, xanthine oxidase, DNA polymerase alpha, steroid, serotonin, dopamine, opioid and cannabinoid targets) with HGNC, UniProt and ChEMBL links.
Added: Six NCI-listed supportive-care drugs (eltrombopag, romiplostim, emapalumab, fostamatinib, ravulizumab, propranolol as Hemangeol) from FDA labels; the chlorambucil-prednisone regimen from the ECOG trial; six earlier Cancer Statistics reports as key papers.
Added: Papers for sixty-one leaders and OECI representatives via Europe PMC author and affiliation matching, each set checked against the person's role.
Changed: Provenance tags (gap-fill, chembl-gap, ctgov-ingest, nci-list and similar) are hidden from reader-facing pills and excluded from similarity scoring; they remain in the JSON API.
Changed: People pages show one plain-English provenance line under the papers table instead of a fetcher note on every row.
Changed: Table cells wrap long tokens site-wide; the models table's paper column uses short labels with the identifier as hover text.
Changed: Nine dead organisation websites replaced with verified current addresses; four Wikipedia links repointed to existing articles; every Wikipedia and organisation link in the corpus checked.
Changed: NCI drug list credits two-letter regimen acronyms; the completeness matcher no longer drops "AC".
Also in 1.0.0: work unreleased since 0.4.0: Molecule3D: ball-and-stick models of small molecules (CPK colours, shaded spheres, depth-sorted bond cylinders with double and triple bonds, drag to rotate, element legend) and smooth backbone ribbons for proteins (Catmull-Rom through the C-alpha trace, per-chain colours, wider on helices and strands, bound drug in ball-and-stick), with a wireframe toggle. Used on product pages, in every molecule thumbnail, and in a new "Solved structures with a drug bound" panel on target pages.
Also in 1.0.0: work unreleased since 0.4.0: PDB snapshots now keep secondary structure from the HELIX and SHEET records (ss); npm run fetch:structures -- --refresh-pdb 5A9U,5DK3 refreshes chosen entries without touching the rest.
Also in 1.0.0: work unreleased since 0.4.0: Startups and investors: company records gain optional stage, ycBatch, investors, funding (sourced rounds, amounts only where the source states them) and acquiredBy; companyType: "investor" for venture funds, corporate venture arms, an accelerator and disease foundations, whose portfolios are derived from backlinks.
Also in 1.0.0: work unreleased since 0.4.0: 62 Y Combinator companies attacking cancer, drawn from the open YC directory dataset and checked one by one (src/data/companies-yc.ts, snapshot with every hit and its decision in src/data/universe-lists/yc-oncology.json); 187 further venture-backed oncology companies across therapeutics, diagnostics, AI, digital care, radiotherapy hardware, surgery and tools (src/data/companies-startups.ts); 69 investors (src/data/investors.ts).
Also in 1.0.0: work unreleased since 0.4.0: /startups/ (stage strip, YC batch chips, filters by stage, modality, cancer, batch, investor and country, most active investors, recently funded) and /investors/; Funding panel on company pages, Portfolio panel on investor pages; stage and investor facets on /companies/; Startups and Investors in the Institutions & people group.

Regulatory events, past 7 days

Dated filings, approvals, letters and label changes recorded on product pages.

2026-09-23 · Galleri · advisory-committee (US): FDA Molecular and Clinical Genetics Panel meeting source

Upcoming readouts and decisions, next 30 days

Decisions, advisory committees, expected readouts and congresses from the readout calendar. Expected dates are editorial estimates.

2026-09-23 · FDA advisory committee: Galleri multi-cancer early detection test (PMA) (confirmed) · Galleri, GRAIL, Multi-cancer early detection (MCED), NHS-Galleri, PATHFINDER 2 · source
2026-10-23 · ESMO Congress 2026, Madrid (23 to 27 October) (confirmed) · European Society for Medical Oncology (ESMO) · source

Corrections, past 7 days

Confirmed factual corrections to the corpus, with the fixing commit.

2026-09-17 · checkmate-548: One record named "CheckMate 548 & CheckMate 143 & CheckMate 498" carried a single registry id (NCT02667587, which is CheckMate 548 only) and yearReported 2020 for all three. They are three separate trials: CheckMate 143 (NCT02017717, JAMA Oncology 2020), CheckMate 498 (NCT02617589, Neuro-Oncology 2023) and CheckMate 548 (NCT02667587, Neuro-Oncology 2022). The glioma history also dated CheckMate 143 to 2017 while the record said 2020. (Reader report by Erion Junior de Andrade, MD, MSc, neurosurgeon, Hospital São José, Santa Casa de Porto Alegre (PR #25), checked against ClinicalTrials.gov and the PubMed records (143, 498, 548)) · split into checkmate-143, checkmate-498, checkmate-548, each with its own registry id, publication, year and outcomes; history entry moved to 2020
2026-09-17 · checkmate-548: The structured overall-survival outcome (28.9 vs 32.1 months) cited academic.oup.com/neuro-oncology/article/25/1/123, which is the CheckMate 498 paper (Omuro et al.), not CheckMate 548 (Lim et al., Neuro-Oncology 2022;24:1935-1949). (Reader report by Erion Junior de Andrade, MD, MSc, neurosurgeon, Hospital São José, Santa Casa de Porto Alegre (PR #25), checked against PubMed (source)) · source set to https://doi.org/10.1093/neuonc/noac116